sentences: Genome-wide association study of Alzheimer's disease brain imaging biomarkers and neuropsychological phenotypes in the EMIF-AD Multimodal Biomarker Discovery dataset Alzheimers disease (AD) is the most frequent neurodegenerative disease with an increasing prevalence in industrialized, ageing populations. AD susceptibility has an established genetic basis which has been the focus of a large number of genome-wide association studies (GWAS) published over the last decade. Most of these GWAS used dichotomized clinical diagnostic status, i.e. case vs. control classification, as outcome phenotypes, without the use of biomarkers. An alternative and potentially more powerful study design is afforded by using quantitative AD-related phenotypes as GWAS outcome traits, an analysis paradigm that we followed in this work. Specifically, we utilized genotype and phenotype data from n=931 individuals collected under the auspices of the European Medical Information Framework for Alzheimers Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study to perform a total of 19 separate GWAS analyses. As outcomes we used five magnetic resonance imaging (MRI) traits and seven cognitive performance traits. For the latter, longitudinal data from at least two timepoints were available in addition to cross-sectional assessments at baseline. Our GWAS analyses revealed several genome-wide significant associations for the neuropsychological performance measures, in particular those assayed longitudinally. Among the most noteworthy signals were associations in or near EHBP1 (EH domain binding protein 1; on chromosome 2p15) and CEP112 (centrosomal protein 112; 17q24.1) with delayed recall in a memory performance test. On the X chromosome, which is often excluded in other GWAS, we identified a genome-wide significant signal near IL1RAPL1 (interleukin 1 receptor accessory protein like 1; Xp21.3). While polygenic score (PGS) analyses showed the expected strong associations with SNPs highlighted in relevant previous GWAS on hippocampal volume and cognitive function, they did not show noteworthy associations with recent AD risk GWAS findings. In summary, our study highlights the power of using quantitative endophenotypes as outcome traits in AD-related GWAS analyses and nominates several new loci not previously implicated in cognitive decline.

labels: genetic and genomic medicine


sentences: Assessing the contribution of rare-to-common protein-coding variants to circulating metabolic biomarker levels via 412,394 UK Biobank exome sequences Genome-wide association studies have established the contribution of common and low frequency variants to metabolic biomarkers in the UK Biobank (UKB); however, the role of rare variants remains to be assessed systematically. We evaluated rare coding variants for 198 metabolic biomarkers, including metabolites assayed by Nightingale Health, using exome sequencing in participants from four genetically diverse ancestries in the UKB (N=412,394). Gene-level collapsing analysis - that evaluated a range of genetic architectures - identified a total of 1,303 significant relationships between genes and metabolic biomarkers (p<1x10-8), encompassing 207 distinct genes. These include associations between rare non-synonymous variants in GIGYF1 and glucose and lipid biomarkers, SYT7 and creatinine, and others, which may provide insights into novel disease biology. Comparing to a previous microarray-based genotyping study in the same cohort, we observed that 40% of gene-biomarker relationships identified in the collapsing analysis were novel. Finally, we applied Gene-SCOUT, a novel tool that utilises the gene-biomarker association statistics from the collapsing analysis to identify genes having similar biomarker fingerprints and thus expand our understanding of gene networks.


sentences:
Temporal trends in hospitalizations and 30-day mortality in older patients during the COVID pandemic from March 2020 to July 2021 ImportancePrevious reports have suggested reductions in mortality risk from COVID-19 throughout the first wave of the COVID-19 pandemic. Mortality changes later in the pandemic and pandemic effects on other types of geriatric hospitalizations are less studied.

ObjectivesTo describe the changes in hospitalizations and 30-day mortality in Stockholm for patients 70+ receiving inpatient geriatric care for COVID-19 and other causes.

DesignObservational study. For patients 70 or older, we present the incidence of 30-day mortality from COVID-19 in the Stockholm region, in relationship to geriatric hospitalizations and 30-day mortality after admission for COVID-19 and other causes.

SettingHospitalizations for patients 70+ from geriatric clinics in Stockholm, Sweden hospitalized for COVID-19 or other causes between March 2020 and July 31, 2021, were included.

ParticipantsThe total number of geriatric hospitalizations for patients 70+ was 5,320 for COVID-19 and 32,243 for non-COVID-19 causes, corresponding to 4,565 individual COVID-19 patients and 19,308 non-COVID-19 patients.

Exposure(s)The date of hospital admission to a geriatric clinic. Main Outcome(s) and Measure(s): 30-day mortality after admission.

ResultsIn patients with COVID-19, the 30-day mortality rate was highest at the beginning of the first wave (29% in March-April 2020), decreased as the first wave subsided (7% July-August), increased again in the second wave (17% November-December), but failed to increase as much in the third wave (11-13% March-July 2021). In non-COVID-19 geriatric patients during the same period, the 30-day mortality presented a similar trend, but with a smaller magnitude of variation (5 to 10%). The number of persons 70 or older testing positive for COVID-19 in Stockholm reached two peaks in 2020 (April and December), fell in January 2021 and then increased again in March-April 2021.

Conclusions and RelevanceDuring the first and second waves, hospital admissions and 30-day mortality after geriatric hospitalization for COVID-19 increased in periods of high community transmission, although the mortality peak was lower in wave 2 than in wave 1. The mortality for non-COVID geriatric cases was lower and more stable but also showed an increase with the pandemic peaks.

KEY POINTSO_ST_ABSQuestionC_ST_ABSMultiple previous reports in different countries and settings have shown higher case fatality ratio or hospitalized case fatality ratio for COVID-19 in the first wave compared to the second wave of the pandemic. However, less is known about how the COVID-19 waves specifically affected the care of geriatric patients, including those with conditions other than COVID.

FindingsThe total number of hospitalizations was 5,320 for COVID-19 and 32,243 for non-COVID-cases. In COVID-patients, the 30-day mortality rate was highest at the beginning of the first wave (29% in March-April 2020), reached 17% at the second wave peak (November-December) followed by 11-13% in the third wave (March-July 2021). The mortality in non-COVID geriatric patients showed a similar trend, but of lower magnitude (5-10%). During the incidence peaks, COVID-19 hospitalizations displaced non-COVID geriatric patients.

MeaningHospital admissions and 30-day mortality after hospitalizations for COVID-19 increased in periods of high community transmission, albeit with decreasing mortality rates from wave 1 to 3, with a possible vaccination effect in wave 3. Thus, the healthcare system could not compensate for the high community spread of COVID-19 during the pandemic peaks, which also led to displacing care for non-COVID geriatric patients. These results are important for planning healthcare resources in future health emergencies.

labels: geriatric medicine


sentences:
Identifying Medication-related Intents from a Bidirectional Text Messaging Platform for Hypertension Management: An Unsupervised Learning Approach BackgroundFree-text communication between patients and providers is playing an increasing role in chronic disease management, through platforms varying from traditional healthcare portals to more novel mobile messaging applications. These text data are rich resources for clinical and research purposes, but their sheer volume render them difficult to manage. Even automated approaches such as natural language processing require labor-intensive manual classification for developing training datasets, which is a rate-limiting step. Automated approaches to organizing free-text data are necessary to facilitate the use of free-text communication for clinical care and research.

ObjectiveWe applied unsupervised learning approaches to 1) understand the types of topics discussed and 2) to learn medication-related intents from messages sent between patients and providers through a bidirectional text messaging system for managing participant blood pressure.

MethodsThis study was a secondary analysis of de-identified messages from a remote mobile text-based employee hypertension management program at an academic institution. In experiment 1, we trained a Latent Dirichlet Allocation (LDA) model for each message type (inbound-patient and outbound-provider) and identified the distribution of major topics and significant topics (probability >0.20) across message types. In experiment 2, we annotated all medication-related messages with a single medication intent. Then, we trained a second LDA model (medLDA) to assess how well the unsupervised method could identify more fine-grained medication intents. We encoded each medication message with n-grams (n-1-3 words) using spaCy, clinical named entities using STANZA, and medication categories using MedEx, and then applied Chi-square feature selection to learn the most informative features associated with each medication intent.

ResultsA total of 253 participants and 5 providers engaged in the program generating 12,131 total messages: 47% patient messages and 53% provider messages. Most patient messages correspond to blood pressure (BP) reporting, BP encouragement, and appointment scheduling. In contrast, most provider messages correspond to BP reporting, medication adherence, and confirmatory statements. In experiment 1, for both patient and provider messages, most messages contained 1 topic and few with more than 3 topics identified using LDA. However, manual review of some messages within topics revealed significant heterogeneity even within single-topic messages as identified by LDA. In experiment 2, among the 534 medication messages annotated with a single medication intent, most of the 282 patient medication messages referred to medication request (48%; n=134) and medication taking (28%; n=79); most of the 252 provider medication messages referred to medication question (69%; n=173). Although medLDA could identify a majority intent within each topic, the model could not distinguish medication intents with low prevalence within either patient or provider messages. Richer feature engineering identified informative lexical-semantic patterns associated with each medication intent class.

ConclusionLDA can be an effective method for generating subgroups of messages with similar term usage and facilitate the review of topics to inform annotations. However, few training cases and shared vocabulary between intents precludes the use of LDA for fully automated deep medication intent classification.

labels: health informatics


sentences:
Elevation of cell-associated HIV-1 RNA transcripts in CSF CD4+ T cells, despite suppressive antiretroviral therapy, is linked to in vivo brain injury ObjectiveDespite effective antiretroviral therapy (ART), brain injury remains prevalent in people living with HIV-1 infection (PLHIV) possibly due to ARTs lack of direct inhibition of transcription with continued local production of viral transcripts and neurotoxic proteins, such as Tat, rather than cell-free whole virion toxicity. We quantified cell-associated (CA) HIV-1 RNA-transcripts in CSF and blood, in relation to proton Magnetic Resonance Spectroscopy (1H MRS) of major brain metabolites, in well characterised PLHIV.

MethodsRNA was extracted from cells in 16 paired samples of CSF and blood, from PLHIV on fully suppressive ART. HIV-1 CA-RNA copies were measured using the highly sensitive Double-R assay and normalized /106 CD4+ T cells. 18-colour flow cytometry was used to count and analyse CD4+ T cells and monocytes in CSF and blood. The concentrations of major brain metabolites from 1H MRS in frontal white matter (FWM), posterior cingulate cortex (PCC), and caudate areas were measured. Brain injury in each voxel was defined using a composite score derived by principal component analysis.

Results14/16 CSF cell samples had quantifiable HIV-1 CA-RNA transcripts, at levels significantly higher than in their PBMCs (median 9,266 vs 185 copies /106 CD4+ T cells; p<0.0001). Higher levels of CSF transcripts were associated with greater brain injury in the FWM (Std {beta}=-0.73; p=0.007) and PCC (Std {beta}=-0.61; p=0.03). CSF cells were 91% memory T cells, equally CD4+ (median 3,605) cells and CD8+ T cells (3,632), but contained much fewer B cells (0.4 %), NK cells (2.0%) and monocytes (3.1%; 378 cells; >90% CD14+CD16+ phenotype). CXCR3+CD49d+integrin {beta}7-negative, CCR5+ CD4+ T cells were significantly enriched in CSF, compared with PBMC (p <0.001). Transcriptional activity in CSF cells was highly correlated with levels of transcriptional activity in CD4+ T cells in PBMC (r=0.76; p=0.002). In contrast, HIV-1 RNA in highly purified monocytes from PBMC was detected in only 6/16 samples.

ConclusionsElevated HIV-1 transcripts in CSF cells were associated with in vivo brain injury, despite suppressive ART. The cellular source is most likely the predominant CXCR3+ CD49d+ integrin{beta}7-CCR5+ memory CD4+ T cells, not monocytes. Inhibitors of transcription to reduce local production of potentially neurotoxic proteins, should be developed.

labels: hiv aids


sentences: SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant Nigeria is the most populated country in Africa with an estimated [~]213 million inhabitants. As of November 2021 there have been three waves of SARS-CoV-2 infection in Nigeria but there has been only one seroprevalence survey conducted to assess the proportion of a population that have been infected, which was performed in December 2020 after the first wave of infection. To provide an update on seroprevalence in Nigeria, we conducted survey at one urban site (n=400) and one rural site (n=402) in Kaduna State, Nigeria during October and November 2021 following the third wave of infection. Seroprevalence for the urban and rural sites was 42.5% and 53.5% respectively (mean 48.0%). Symptoms associated with seropositivity were identified for each site. The overall seroprevalence among unvaccinated individuals was 45.4%. The data indicates an infection rate in Kaduna State at least 387 times greater than that derived from cases confirmed by PCR. Extrapolating to the whole of Nigeria, it would suggest there has been at least 96.7 million infections (compared to 206,138 confirmed cases at the time of surveillance). The work presented here will inform public health policy and deployment strategies for testing, treatment, and vaccination in Nigeria, and provide a baseline for SARS-CoV-2 seroprevalence in Nigeria immediately prior to the spread of the Omicron variant.

labels: infectious diseases


sentences: Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with increased protection The RTS,S/AS01E vaccine targets the circumsporozoite protein (CSP) of the Plasmodium falciparum parasite. Using protein microarrays, levels of IgG to 1,000 P. falciparum antigens were measured in 2,138 infants (age 6-12 weeks) and children (age 5-17 months) from 6 African sites of the phase 3 trial, sampled before and at four longitudinal visits after vaccination. One month post-vaccination, IgG responses to 17% of all probed antigens showed differences between RTS,S/AS01E and comparator vaccination groups, whereas no pre-vaccination differences were found. A small subset of antigens presented IgG levels reaching 4- to 8-fold increases in the RTS,S/AS01E group, comparable in magnitude to anti-CSP IgG levels ([~]11-fold increase). They were strongly cross-correlated and correlated with anti-CSP levels, waning similarly over time and re-increasing with the booster dose. Such an intriguing phenomenon may be due to cross-reactivity of anti-CSP antibodies with these antigens. RTS,S/AS01E vaccinees with strong off-target IgG responses had an estimated lower clinical malaria incidence after adjusting for age group, site and post-vaccination anti-CSP levels. RTS,S/AS01E-induced IgG may bind strongly not only to CSP, but to unrelated malaria antigens, and this seems to either confer, or at least be a marker of, increased protection from clinical malaria.


sentences: Preserved Omicron Spike specific antibody binding and Fc-recognition across COVID-19 vaccine platforms Despite the dramatic spread of Omicron globally, even among highly vaccinated populations, death rates have not increased concomitantly. These data argue that alternative immune mechanisms, beyond neutralization, may continue to confer protection against severe disease. Beyond their ability to bind and block infection, antibodies contribute to control and clearance of multiple infections via their ability to direct antiviral immunity via Fc-effector mechanisms. Thus, here we probed the ability of vaccine induced antibodies, across three COVID-19 vaccines, to drive Fc-effector activity against Omicron. Despite the significant loss of IgM, IgA and IgG binding to the Omicron Receptor Binding Domain (RBD) across BNT162b2, mRNA-1273, and CoronaVac vaccines, stable isotype binding was observed across all of these vaccines to the Omicron Spike. Compromised RBD binding IgG was accompanied by a significant loss of cross RBD-specific antibody Fc{gamma}-receptor binding by the CoronaVac vaccine, but preservation of RBD-specific Fc{gamma}R2a and Fc{gamma}3a binding across the mRNA vaccines. Conversely, Spike-specific antibodies exhibited persistent binding to Fc{gamma}-receptors, across all three vaccines, albeit higher binding was observed with the mRNA vaccines, marked by a selective preservation of Fc{gamma}R2a and Fc{gamma}3a binding antibodies. Thus, despite the significant to near complete loss of Omicron neutralization across several vaccine platforms against Omicron, vaccine induced Spike-specific antibodies continue to recognize the virus and recruit Fc-receptors pointing to a persistent capacity for extra-neutralizing antibodies to contribute Omicron disease attenuation.


sentences:
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial IMPORTANCEThe effectiveness of monoclonal antibodies (mAbs), casirivimab and imdevimab, and sotrovimab, for patients with mild to moderate COVID-19 from the Delta variant is unknown.

OBJECTIVETo evaluate the effectiveness of mAbs for the Delta variant compared to no treatment, and the comparative effectiveness between mAbs.

DESIGN, SETTING, AND PARTICIPANTSTwo parallel studies among patients who met Emergency Use Authorization criteria for mAbs from July 14, 2021 to September 29, 2021: i.) prospective observational cohort study comparing mAb treatment to no mAb treatment and, ii.) Bayesian adaptive randomized trial comparing the effectiveness of casirivimab-imdevimab versus sotrovimab. In the observational study, we compared eligible patients who received mAb at an outpatient infusion center at UPMC, to nontreated patients with a positive SARS-CoV-2 test. In the comparative effectiveness trial, we randomly allocated casirivimab-imdevimab or sotrovimab to patients presenting to infusion centers and emergency departments, per system therapeutic interchange policy.

EXPOSUREIntravenous mAb per their EUA criteria.

MAIN OUTCOMES AND MEASURESFor the observational study, risk ratio estimates for hospitalization or death by 28 days were compared between mAb treatment to no mAb treatment using propensity matched models. For the comparative effectiveness trial, the primary outcome was hospital-free days (days alive and free of hospital) within 28 days, where patients who died were assigned -1 day) in a Bayesian cumulative logistic model, adjusted for treatment location, age, sex, and time. Inferiority was defined as a 99% posterior probability of an odds ratio <1. Equivalence was defined as a 95% posterior probability that the odds ratio is within a given bound.

RESULTSAmong 3,558 patients receiving mAb, the mean age was 54 (SD 18 years), 1,511 (43%) were treated in an infusion center, and 450 (13%) were hospitalized or died by day 28. In propensity matched models, mAb treatment was associated with reduced risk of hospitalization or death compared to no treatment (risk ratio (RR)=0.40, 95% CI: 0.28-0.57). Both casirivimab and imdevimab (RR=0.31, 95% CI: 0.20-0.50), and sotrovimab (RR=0.60, 95% CI: 0.37-1.00) reduced hospitalization or death compared to no mAb treatment. Among patients allocated randomly to casirivimab and imdevimab (n=2,454) or sotrovimab (n=1,104), the median hospital-free days were 28 (IQR 28-28) for both groups, 28-day mortality was 0.5% (n=12) and 0.6% (n=7), and hospitalization by day 28 was 12% (n=291) and 12% (n=140), respectively. Compared to casirivimab and imdevimab, the median adjusted odds ratio for hospital-free days was 0.88 (95% credible interval, 0.70-1.11) for sotrovimab. This odds ratio yielded 86% probability of inferiority of sotrovimab versus casirivimab and imdevimab, and 79% probability of equivalence.

CONCLUSIONS AND RELEVANCEIn non-hospitalized patients with mild to moderate COVID-19 due to the Delta variant, casirivimab and imdevimab and sotrovimab were both associated with a reduced risk of hospitalization or death. The comparative effectiveness of mAbs appeared similar, though prespecified criteria for statistical inferiority or equivalence were not met.

TRIAL REGISTRATIONClinicalTrials.gov: NCT04790786

Key PointsO_ST_ABSQuestionC_ST_ABSIn non-hospitalized patients with mild to moderate COVID-19 due to the Delta variant, what is the effectiveness of monoclonal antibodies (mAb) compared to no treatment, and what is the comparative effectiveness between mAb?

FindingsAmong 3,069 patients, mAb treatment (casirivimab and imdevimab or sotrovimab) was associated with reduced risk of hospitalization or death by 28 days compared to no treatment (risk ratio=0.40, 95% CI: 0.28-0.57). In a Bayesian randomized comparative effectiveness trial of casirivimab and imdevimab vs. sotrovimab in 3,558 patients, the median hospital-free days were 28 days for both groups. Compared to casirivimab-imdevimab, the median adjusted odds ratio for hospital-free days was 0.88 (95% credible interval, 0.70-1.11) for sotrovimab, an 86% probability of inferiority of sotrovimab versus casirivimab and imdevimab, and 79% probability of equivalence.

MeaningIn non-hospitalized patients with mild to moderate COVID-19 due to the Delta variant, casirivimab and imdevimab and sotrovimab were associated with reduced risk of hospitalization or death compared to no treatment. The comparative effectiveness of mAbs appeared similar, though prespecified criteria for statistical inferiority or equivalence were not met.


sentences:
Smoking, race, ancestry and prospective abstinence BackgroundFactors influencing cessation include biopsychosocial characteristics, treatments and responses to treatment. The first cessation trial designed to assess cessation disparities between African American and White cigarette smokers demonstrated that socioeconomic, treatment, psychosocial and smoking characteristics explained cessation disparities. Ongoing translational efforts in precision cessation treatment grounded in genetically informed biomarkers have identified cessation differences by genotype, metabolism, ancestry and treatment.

MethodsIn planned analyses, we evaluated six smoking-related measures, demographic and socioeconomic covariates, and prospective abstinence (7-day point prevalence at 12 weeks with bupropion, nicotine replacement and counseling treatments). We assessed concurrent and predictive validity in two covariate models differing by inclusion of Office of Management and Budget (OMB) race/ethnicity or genomic ancestry.

ResultsWe studied Pharmacogenetic Study participants (N=456, mean age 49.5 years, 41.5% female, 7.4% African American, 9.4% Multiracial, 6.5% Other, and 6.7% Hispanic). Cigarettes per day (OR=0.95, P<.001), Fagerstrom score (OR=0.89, P<=.014), Time-To-First-Cigarette (OR=0.75, P<=.005) and predicted urinary nicotine metabolite ratio (OR=0.57, P<=.039) were associated with abstinence. OMB African American race (ORs from 0.31 and 0.35, p-values<=.007) and African genomic ancestry (ORs from 0.21 and 0.26, p-values<=.004) were associated in all abstinence models.

ConclusionsFour smoking-related measures exhibited association with abstinence, including predicted nicotine metabolism based on a novel genomic model. African genomic ancestry was independently associated with reduced abstinence. Treatment research that includes social, psychological, treatment and biological factors is needed to reduce cessation disparities.

ImplicationsO_LIThis is the first application of a statistical learning model of the urinary nicotine metabolite ratio to cessation. Results are concordant with biochemical and genetic models of the plasma nicotine metabolite ratio in multiethnic samples.
C_LIO_LIThe urinary ratio exhibits the largest standardized effect size of four smoking-related measures associated with cessation (time-to-first cigarette, total Fagerstrom score and cigarettes per day were the others).
C_LIO_LIThe social construct of African American race and genomic African ancestry are significant covariates in all cessation models.
C_LIO_LIResults point to social and biological mechanisms requiring investigation in larger samples to understand and reduce cessation health disparities.
C_LI

labels: addiction medicine


sentences: A model based on a high-resolution flux matrix explains the spread of diseases in a spatial network and the effect of mitigation strategies Propagation of an epidemic across a spatial network of communities is described by a variant of the SIR model accompanied by an intercommunity infectivity matrix. This matrix is estimated from fluxes between communities, obtained from cell-phone tracking data recorded in the USA between March 2020 and February 2021. We have applied this model to the 2020 dynamics of the SARS-CoV-2 pandemic. We find that the numbers of susceptible and infected individuals predicted by the model agree with the reported cases in each community by fitting just one global parameter representing the frequency of interaction between individuals. The effect of "shelter-in-place" policies introduced across the USA at the onset of the pandemic is clearly seen in our results. We then consider the effect that alternative policies would have had, namely restricting long-range travel. We find that this policy is successful in decreasing the epidemic size and slowing down the spread, at the expense of a substantial restriction on mobility as a function of distance. When long-distance mobility is suppressed, this policy results in a traveling wave of infections, which we characterize analytically. In particular, we show the dependence of the wave velocity and profile on the transmission parameters. Finally, we discuss a policy of selectively constraining travel based on an edge-betweenness criterion.

labels: epidemiology


sentences: Testing the phenotypic decanalization hypothesis: social determinants of hyperglycemia and type 2 diabetes in adult urban Argentinian population Type 2 diabetes, one of the major causes of death and disability worldwide, is characterized by problems in the homeostasis of blood glucose. Current preventive policies focus mainly on individual behaviors (diet, exercise, salt and alcohol consumption). Recent hypotheses state that the higher incidence of metabolic disease in some human populations may be related to phenotypic decanalization causing a heightened phenotypic variance in response to unusual or stressful environmental conditions, although the nature of these conditions is under debate. Our aim was to explore variability patterns of fasting blood glucose to test phenotypic decanalization as a possible explanation of heightened prevalence for type 2 diabetes in some groups and to detect variables associated with its variance using a nation-wide survey of Argentinian adult population. We found patterns of higher local variance for fasting glycemia associated with lower income and educational attainment. We detected no meaningful association of glycemia or its variability with covariates related to individual behaviors (diet, physical activity, salt or alcohol consumption). Our results were consistent with the decanalization hypothesis for fasting glycemia, which appears associated to socioeconomic disadvantage. We therefore propose changes in public policy and discuss the implications for data gathering and further analyses.


sentences:
The use of Cohort Size Shrinkage Index (CSSI) to quantify regional famine intensity during the Chinese famine of 1959-61 There has been a growing interest in studying the causes and impact of the Great Chinese Famine of 1959-61. The Cohort Size Shrinkage Index (CSSI) is the most widely used measure to examine famine intensity and was used in at least 28 Chinese famine studies to date. We examined the potential impact of violations of three requirements for a valid CSSI measure: reliable information on cohort size by year of birth; a stable trend of cohort size by year of birth; and the absence of significant regional migration. We used data from the 1% China 2000 Census to examine the trend of cohort size over time and concentrated on the time window between 1950-70 to exclude policies and events with a large impact on birth trends other than the famine itself.

Across China we established a significant difference in cohort size trends between pre-famine births and post-famine births, violating one of the main requirements for a valid CSSI measure. This leads to systematic differences in CSSI depending on what non-famine years are selected for comparison. At the province level, CSSIs estimated based on pre- & post-famine births tend to overestimate famine intensity at higher exposure levels and underestimate intensity at lower levels compared to CSSIs based on pre-famine births alone. This is problematic and demonstrates that the CSSI is not as robust an estimator of famine intensity as had been assumed previously. We recommend therefore that all CSSI should be based on pre-famine birth trends.

Using data from Sichuan province, we demonstrate a less pronounced dose-response relation between famine intensity and tuberculosis outcomes using pre-famine based CSSI as compared to reported patterns based on pre- & post-famine based CSSI. We encourage researchers to re-examine their results of Chinese famine studies as local differences in cohort size of pre-famine and post-famine births may lead to significant discrepancies of CSSI estimation and change the interpretation of their findings.


sentences: Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada While it is now evident that Omicron is rapidly replacing Delta, largely due to immune escape, it is less clear how the severity of Omicron compares to Delta. In Ontario, we sought to examine hospitalization and death associated with Omicron, as compared to cases infected with Delta. We conducted a matched cohort study, considering time to hospitalization or death as the outcome. Cases were matched on gender, age, vaccination status, health region and onset date. We identified 29,594 Omicron cases that met eligibility criteria, of which 11,622 could be matched with at least one Delta case (N=14,181). There were 59 (0.51%) hospitalizations and 3 (0.03%) deaths among matched Omicron cases, compared to 221 (1.6%) hospitalizations and 17 (0.12%) deaths among matched Delta cases. The risk of hospitalization or death was 65% lower (hazard ratio, HR=0.35, 95%CI: 0.26, 0.46) among Omicron cases compared to Delta cases, while risk of intensive care unit admission or death was 83% lower (HR=0.17, 95%CI: 0.08, 0.37). While severity is likely to be reduced, the absolute number of hospitalizations and impact on the healthcare system may nevertheless be significant due to the increased transmissibility of Omicron.


sentences:
SIR model for assessing the impact of the advent of Omicron and mitigating measures on infection pressure and hospitalization needs BackgroundOn 26 November 2021, the world health organization (WHO) designated the coronavirus SARS-CoV-2 B.1.1.529 a variant of concern, named Omicron (WHO, 2021a). As of December 16, Omicron has been detected in 89 countries (WHO, 2021b). The thread posed by Omicron is highly uncertain.

Methods and findingsFor the analysis of the impact of Omicron on infection pressure and hospitalization needs we developed an open-source stochastic SIR (Susceptible-Infectious-Removed) fast-model for simulating the transmission in the transition stage from the prevailing variant (most often Delta) to Omicron. The model is capable to predict trajectories of infection pressure and hospitalization needs, considering (a) uncertainties for the (Omicron) parametrization, (b) pre-existing vaccination and/or partial immunity status of the population, and demographic specific aspects regarding reference hospitalization needs, (c) effects of mitigating measures including social distancing and accelerated vaccination (booster) campaigns.

ConclusionsThe SIR model approach yields results in fair agreement with Omicron transmission characteristics observed in South Africa and prognosis results in Europe (UK and Netherlands). The equations underlying the SIR formulation allows to effectively explore the effect of Omicron parametrization on anticipated infection growth rates and hospitalization rates relative to the prevailing variant. The models are online available as open source on GitHub.

One Sentence Summaryfast-model for the impact of Omicron


sentences:
Estimating the impact of implementation and timing of COVID-19 vaccination program in Brazil: a counterfactual analysis BackgroundThe vaccines developed in 2020-2021 against the SARS-CoV-2 virus were designed to prevent severity and deaths due to COVID-19. However, estimates of the effectiveness of vaccination campaigns in achieving these goals remain a methodological challenge. In this work, we developed a Bayesian statistical model to estimate the number of deaths and hospitalisations avoided by vaccines in older adults in Brazil.

MethodsWe fit a linear model to predict the number of deaths and hospitalisations in older adults as a function of vaccination coverage and of casualties in younger adults. We then used this model to perform counterfactual analysis, simulating alternative scenarios without vaccination or with earlier vaccination roll-out. We estimated direct effects of COVID-19 vaccination by computing the difference between hypothetical and realised scenarios.

ResultsWe estimated that more than 165 thousand individuals above 60 y.o. were not hospitalised due to COVID-19 in the first seven months of the vaccination campaign. An additional contingent of 100 thousand hospitalisations could have been avoided if vaccination had started earlier. We also estimated that more than 75 thousand lives were saved by vaccination in the period analysed for the same age group, and that additional 48 thousand lives could have been saved had the Brazilian Government started the vaccination programme earlier.

ConclusionsOur estimates provide a lower bound for vaccination impacts in Brazil, demonstrating the importance of preventing suffering and loss of the older adults Brazilians. Once vaccines were approved, an early vaccination roll-out could have saved many more lives, especially when facing a pandemic.

O_TEXTBOXKey messagesO_LIThe coronavirus pandemic affected more severely older adults, which presented the higher rates of hospitalisation and deaths related to COVID-19, leading most countries, as Brazil, to start the vaccination following a decreasing age scheme.
C_LIO_LIEvaluating a hypothetical scenario of the absence of vaccines, we estimated the number of hospitalisations and deaths that Brazil has prevented due to the vaccination roll-out applied to persons above 60 years old: {approx}167,000 hospitalisations did not occur and {approx}77,000 lives were saved due to the vaccines.
C_LIO_LIThe estimates for the number of lives saved and the avoided hospitalisations are a lower bound for the actual number because only the direct effects for the older adults were taken into account, and no herd immunity effect was considered.
C_LIO_LIEvaluating another hypothetical scenario, considering an eight weeks earlier rollout, Brazil could have saved a minimum of additional {approx}48,000 lives and avoided another {approx}100,000 hospitalisations compared to what happened.
C_LI

C_TEXTBOX


sentences: Humoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease Herein, we evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with IBD. All patients were seropositive and had higher antibody concentrations after the third dose than after completion of the two-dose primary series.

labels: gastroenterology


sentences: Gestational age and infection are greater predictors of placental histopathology than maternal prepregnancy BMI. The placenta undergoes morphological and functional adaptions to adverse exposures during pregnancy. The effects of suboptimal maternal body mass index (BMI), preterm birth, and infection on placental histopathological phenotypes remain unclear, despite the association between these conditions and poor offspring outcomes. We hypothesized that suboptimal maternal prepregnancy BMI and preterm birth (with and without infection) would associate with altered placental maturity and morphometry, and that altered placental maturity would associate with poor birth outcomes. Clinical data and human placentae were collected from 96 pregnancies where mothers were underweight, normal weight, overweight, or obese, without other major complications. Placental histopathological characteristics were scored with an anatomical pathologist. Associations between maternal BMI, placental pathology (immaturity and hypermaturity), placental morphometry, and infant outcomes were investigated at term and preterm, with and without infection. Fetal vascular endothelium volumetric proportion was decreased, whereas syncytial knot volumetric proportion was increased, in placentae from preterm pregnancies with chorioamnionitis compared to term placentae. At term and preterm, pregnancies with overweight and obesity had a high percentage increase in proportion of immature placentae compared to normal weight. Placental maturity did not associate with infant birth outcomes. We observed placental hypermaturity and altered placental morphometry among preterm pregnancies with chorioamnionitis, suggestive of altered placental development, which may inform about pregnancies susceptible to preterm birth and infection. Our data increase our understanding of how common metabolic exposures and preterm birth, in the absence of other comorbidities or perinatal events, potentially contribute to poor pregnancy outcomes and the programming of offspring development.

labels: pathology


sentences: Utilization of a SARS-CoV-2 Variant Assay for the Rapid Differentiation of Omicron and Delta The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529), creates a diagnostic vacuum, since differentiation of Omicron from Delta relies on relatively slow next generation sequencing (NGS) technology delaying epidemiologic understanding and therapeutic intervention. The RUO SARS-CoV-2 Variant Set 1 Test (RSCov2V1) RT-PCR for detection of spike gene N501Y, E484K and del69-70 was designed to differentiate Alpha from Beta and Gamma variants. While Delta lacks these three variants, Omicron has the N501Y and del69-70 mutation. We submitted 88 samples for RSCov2V1 identifying 9 samples with the N501Y and del69-70 mutations while all other samples (79) were negative for all three variants. 9/9 samples with the del69-70 and N501Y were identified by NGS to be Omicron while 47/47 other samples assessed by NGS were confirmed to be Delta family variants. We demonstrate here that an immediately available RT-PCR assay for detection of spike gene N501Y and del69-70 can be utilized to rapidly differentiate Omicron from Delta variants in the proper epidemiologic context


sentences:
Predicting risk of pancreatic cancer in individuals with new-onset type-2 diabetes in primary care: protocol for the development and validation of a clinical prediction model (QPancreasD) BackgroundPancreatic cancer continues to have an extremely poor prognosis in part due to late diagnosis. 25% of pancreatic cancer patients have a prior diagnosis of diabetes, and hence identifying individuals at risk of pancreatic cancer in those with recently diagnosed type 2 diabetes may be a useful opportunity to identify candidates for screening and early detection. In this study, we will comparatively evaluate regression and machine learning-based clinical prediction models for estimating individual risk of developing pancreatic cancer two years after type 2 diabetes diagnosis.

MethodsIn the development dataset, we will include adults aged 30-84 years with incident type-2 diabetes registered with QResearch primary care database. Patients will be followed up from type-2 diabetes diagnosis to first diagnosis of pancreatic cancer as recorded in any one of primary care records, hospital episode statistics, cancer registry data, or death records. Cox-proportional hazards models will be used to develop a risk prediction model for estimating individual risk of developing pancreatic cancer during up to 2 years of follow-up. We will perform variable selection using a combination of clinical and statistical significance approach i.e. HR <0.9 or >1.1 and p<0.01. Linear predictors and baseline survivor function at 2 years will be used to compute absolute risk predictions.

Internal-external cross-validation (IECV) framework across geographical regions within England will be used to assess performance and pooled using random effects meta-analysis using: (i) model fit in terms of variation explained by the model Royston & Sauerbreis R2D, (ii) calibration slope and calibration-in-the-large, and (iii) discrimination measured in terms of Harrells C and Royston & Sauerbreis D-statistic.

Further, we will evaluate machine learning (ML) approaches for the clinical prediction model using neural networks (NN) and XGBoost. The model predictors and performance of these will be compared with the results of those derived from the regression-based strategy.

DiscussionThe proposed study will develop and validate a novel risk prediction model to aid early diagnosis of pancreatic cancer in patients with new-onset diabetes in primary care. With an enhanced decision-risk tool for use at point-of care by general practitioners to assess pancreatic cancer risk, it may improve decision-making so that at-risk patients are rapidly prioritised to aid early diagnosis of pancreatic cancer in patients with newly diagnosed diabetes.

labels: primary care research


sentences:
A simple and quick PCR based method for detection of Omicron variant of SARS-CoV-2 SARS-CoV-2 pandemic has changed the global landscape since last two years. Against many challenges posed by the COVID-19 pandemic to the humanity, the pace of solutions created by mankind is exemplary; diagnostics, vaccines, alternate therapies, to name a few. With a rapidly changing virus strain, its early identification in the community can be a quick solution to trace the individuals and thus control its spread. This paper describes PCR based quick method for differentiation of Omicron variant of SARS-CoV-2 from other variants. Timely identification of this new variant will enable better management of pandemic control in the population.

Graphical Abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/21268053v1_ufig1.gif" ALT="Figure 1">
View larger version (24K):
org.highwire.dtl.DTLVardef@7a5e9forg.highwire.dtl.DTLVardef@1da2339org.highwire.dtl.DTLVardef@3eab87org.highwire.dtl.DTLVardef@6f3258_HPS_FORMAT_FIGEXP  M_FIG C_FIG

labels: public and global health


sentences:
Towards environmental detection of Chagas disease vectors and pathogen BackgroundAccurate surveillance of triatomine household infestation is crucial for Chagas disease vector control. However, no gold standard detection method with high levels of sensitivity or specificity is currently available. Several intrinsic features of triatomine bug behaviour and the lifecycle of Trypanosoma (T.) cruzi lead to deposition of environmental DNA (eDNA) in infested houses. This study evaluated the use of FTA cards and cotton-tipped swabs as low-technology, cost-effective tools for simultaneous detection of T. cruzi and vector eDNA in the laboratory and field.

Methods/Principal FindingsThis study had two components: (1) laboratory evaluation and optimisation of QIAcard(R) FTA(R) classic cards to detect Rhodnius (R.) prolixus eDNA by altering five different environmental variables (darkness, triatomine number, temperature, feeding status and degradation at ambient temperature); (2) detection of R. prolixus and T. cruzi eDNA from cotton-tipped house wall swabs from an endemic region in Casanare Department, Colombia. eDNA was extracted from all specimens and amplified using a multiplex TaqMan qPCR assay targeting the R. prolixus 12S rRNA gene and T. cruzi satellite DNA region. R. prolixus eDNA from five 3rd/4th instar nymphs was successfully amplified from FTA cards after as little as 15 minutes of contact time under standard insectary conditions. Factors significantly increasing eDNA detection from FTA cards were increasing temperature from 21{degrees}C to 27-32{degrees}C, triatomine bug density from 1-25 bugs and recent blood-feeding. eDNA was detectable from FTA cards stored at room temperature for at least two weeks. In cotton-tipped swabs from the field, the sensitivity and specificity of R. prolixus eDNA detection was 60.6% (n=20/33) and 100% (n=33/33), respectively. T. cruzi eDNA was amplified from 93.9% (n=31/33) of infested houses.

Conclusions/SignificanceFTA cards are a highly sensitive tool for entomological surveillance of R. prolixus and exhibit little variability under different environmental conditions. Additionally, cotton-tipped swabs are a relatively sensitive tool for entomological and parasitological surveillance of R. prolixus and T. cruzi in situ, but more feasible due to low cost. Both methods could be utilised by citizen science initiatives to contribute to the control of Chagas disease in endemic communities.

Author SummaryChagas disease vector control relies on prompt, accurate identification of houses infested with triatomine bugs for targeted insecticide spraying. However, most current detection methods are laborious, lack standardization, have substantial operational costs and limited sensitivity, especially when triatomine bug densities are low or highly focal. We evaluated the use of FTA cards or cotton-tipped swabs to develop a low-technology, non-invasive method of detecting environmental DNA (eDNA) from both triatomine bugs and Trypanosoma cruzi for use in household surveillance in eastern Colombia, an endemic region for Chagas disease. Study findings demonstrated that FTA cards are a sensitive tool for detection of Rhodnius prolixus eDNA at temperatures between 21-32{degrees}C, deposited by individual, recently blood-fed nymphs. Additionally, cotton-tipped swabs are a relatively sensitive tool for field sampling of both T. cruzi and R. prolixus eDNA in infested households and are arguably more feasible due to their lower cost. eDNA detection should not yet replace current surveillance tools, but instead be evaluated in parallel as a more sensitive, higher-throughput, lower cost alternative. eDNA collection requires virtually no skills or resources in situ and therefore has the potential to be implemented in local endemic communities as part of citizen science initiatives to control Chagas disease transmission.


sentences:
Assessing Immunity by Quantitative Measurement of SARS-CoV-2 IgG Antibodies in Fingerstick Samples COVID-19 has affected billions of people around the world directly or indirectly. The response to the pandemic has focused on preventing the spread of the disease and improving treatment options. Diagnostic technologies have played a key role in this response since the beginning of the pandemic. As vaccines and other treatments have been developed and deployed, interest in understanding and measuring the individual level of immune protection has increased. Historically, use of antibody titers to measure systemic immunity has been constrained by an incomplete understanding of the relationship between antibodies and immunity, the lack of international standards for antibody concentration to enable cross-study comparisons, and insufficient clinical data to allow for the development of robust antibody-immunity models.

However, these constraints have recently shifted. With a deeper understanding of antibodies, the promulgation of WHO antibody standards, and the development of immunity models using datasets from multiple COVID-19 vaccine trials, certain types of quantitative antibody tests may now provide a way to monitor individual or community immunity against COVID-19. Specifically, tests that quantitate the concentration of anti-RBD IgG -antibodies that target the receptor binding domain of the S1 spike protein component of the SARS-CoV-2 virus - show promise as a useful and scalable measure of the COVID-19 immunity of both individuals and communities. However, to fulfill this promise, a rapid and easy-to-administer test is needed.

To address this important clinical need, Brevitest deployed its point-of-care-capable technology platform that can run a rapid (<15 minute), quantitative antibody test with a sample of 10 l of whole blood from a fingerstick. The test we validated on this platform measures the concentration of anti-RBD IgG in Binding Antibody Units per milliliter (BAU/mL) per WHO Reference Standard NIBSC 20/136.

In this paper, we present studies used to characterize the Brevitest anti-RBD IgG assay and evaluate its clinical performance, lower limits of measurement, precision, linearity, interference, and cross-reactivity. The results demonstrate the ability of this assay to measure a patients anti-RBD IgG concentration. This information, together with models developed from recent COVID-19 vaccine clinical trials, can provide a means of assessing the current level of immune protection of an individual or community against COVID-19 infection.


sentences:
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies BackgroundPatients with Multiple Sclerosis (pwMS) treated with anti-CD20 or fingolimod showed a reduced humoral response to mRNA-based SARS-CoV-2 vaccines, while the degree of such responses is unimpaired and similar in pwMS treated with other disease modifying therapies (DMTs), or untreated. However, the nature of the SARS-CoV-2 vaccine-induced immune response is based also on cellular immunity and there is emerging evidence that anti-SARS-CoV-2 specific CD4 and CD8 T cell responses can be detected after vaccination also in patients with low antibody levels. In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection and to identify correlates of reduced protection in frail vaccinated pwMS on different DMTs.

MethodsWe designed a long term clinical follow-up of the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis), a prospective multicenter cohort study enrolling pwMS scheduled for SARS-CoV-2 vaccination with mRNA vaccines and tested for SARS-CoV-2 antibodies before and after the second vaccine dose. These patients were followed with periodic phone calls up to a mean time of 6 months, and all the SARS-CoV-2 breakthrough infections were registered. The impact of DMTs on cumulative incidence of breakthrough Covid-19 cases was presented by Kaplan-Meier curves. A multivariable logistic model was run to assess factors associated to a higher risk of breakthrough infections.

Findings1705 pwMS (81.6% BNT162b2 and 18.4% mRNA-1273) had a full vaccination cycle (2 vaccine doses, 21/28 days apart). Of them, 1509 (88.5%) had blood assessment 4 weeks after the second vaccine dose. During follow-up, 23 breakthrough Covid-19 infections (cumulative incidence: 1.5%, SE=0.3%) were detected after a mean of 108 days after the second dose (range, 18-230). Of them, 9 were on ocrelizumab, one on rituximab, 4 on fingolimod, 6 on dimethyl-fumarate, one on teriflunomide, and 2 were untreated. Just two cases (a woman on ocrelizumab and a man on teriflunomide) required hospitalization. The probability to be infected was associated only with SARS-CoV-2 antibody levels measured after 4 weeks from the second vaccine dose (HR=0.63, p=0.007); an antibody level of 660 U/mL was calculated as the cutoff for higher risk of infection.

InterpretationOur data show that the risk of breakthrough SARS-CoV-2 infections is mainly associated with reduced levels of the virus-specific humoral immune response.

FundingFISM [2021/Special-Multi/001]; the Italian Ministry of Health grant  Progetto Z844A 5x1000. Italian Ministry of Health: Ricerca Corrente to IRCCS Ospedale Policlinico San Martino.

labels: neurology


sentences:
Humoral and cellular immune responses to SARS CoV-2 vaccination in Persons with Multiple Sclerosis and NMOSD patients receiving immunomodulatory treatments BackgroundVaccination against SARS CoV-2 results in excellent personal protection against a severe course of COVID19. In persons with Multiple Sclerosis (PwMS) vaccination efficacy may be reduced by immunomodulatory medications.

ObjectiveTo assess the vaccination induced cellular and humoral immune response in PwMS receiving disease modifiying therapies.

MethodsIn a monocentric observational study on PwMS and patients with Neuromyelitis optica we quantified the cellular and humoral immune responses to SARS CoV-2.

ResultsPwMS receiving Glatirameracetate, Interferon-{beta}, Dimethylfumarate, Cladribine or Natalalizumab had intact humoral and cellular immune responses following vaccination against SARS CoV-2. B-cell depleting therapies reduced B-cell responses but did not affect T cell responses. S1P inhibitors strongly reduced humoral and cellular immune responses.

There was a good agreement between the Interferon gamma release assay and the T-SPOT assay used to measure viral antigen induced T-cell responses.

ConclusionThis study demonstrates that S1P inhibitors impair the cellular and humoral immune response in SARS CoV-2 vaccination, whereas patients receiving B-cell depleting therapies mount an intact cellular immune response. These data can support clinicians in counselling their PwMS and NMOSD patients during the COVID 19 pandemic.


sentences:
Identification of a novel proteomic Biomarker in Parkinson's Disease: Discovery and Replication in Blood, brain and CSF Biomarkers to aid diagnosis and delineate progression of Parkinsons Disease (PD) are vital for targeting treatment in the early phases of disease. Here, we aim to discover a multi-protein panel representative of PD and make mechanistic inferences from protein expression profiles within the broader objective of finding novel biomarkers.

We used aptamer-based technology (SomaLogic(R)) to measure proteins in 1,599 serum samples, 85 CSF samples and 37 brain tissue samples collected from two observational longitudinal cohorts (Oxford Parkinsons Disease Centre and Tracking Parkinsons) and the PD Brain Bank, respectively. Random forest machine learning was performed to discover new proteins related to disease status and generate multi-protein expression signatures with potential novel biomarkers. Differential regulation analysis and pathway analysis was performed to identify functional and mechanistic disease associations.

The most consistent diagnostic classifier signature was tested across modalities (CSF AUC = 0.74, p-value = 0.0009; brain AUC = 0.75, p-value = 0.006; serum AUC = 0.66, p-value = 0.0002). In the validation dataset we showed that the same classifiers were significantly related to disease status (p-values < 0.001). Differential expression analysis and Weighted Gene Correlation Network Analysis (WGCNA) highlighted key proteins and pathways with known relationships to PD. Proteins from the complement and coagulation cascades suggest a disease relationship to immune response.

The combined analytical approaches in a relatively large number of samples, across tissue types, with replication and validation, provides mechanistic insights into the disease as well as nominating a protein signature classifier that deserves further biomarker evaluation.


sentences:
Arachnoid granulations may be protective against the development of shunt dependent chronic hydrocephalus after aneurysm subarachnoid hemorrhage Background and PurposeChronic hydrocephalus may develop as a sequela of aneurysmal subarachnoid hemorrhage, requiring long-term cerebrospinal fluid shunting. Several clinical predictors of chronic hydrocephalus and shunt dependence have been proposed. However, no anatomical predictors have been identified.

Materials and MethodsA retrospective cohort study was performed including 61 patients with aneurysmal subarachnoid hemorrhage. Clinical characteristics were noted for each patient including presentation World Federation of Neurosurgical Societies grade, modified Fischer grade, aneurysm characteristics, requirement for acute and chronic cerebrospinal fluid diversion, and 3-month modified Rankin scale. CT images were evaluated to determine the Evans index and to enumerate the number of arachnoid granulations. Association between the clinical characteristics with ventriculoperitoneal shunt insertion and the 3-month modified Rankin scale were assessed.

ResultsThe initial Evans index was positively associated with mFisher grade and age, but not the number of arachnoid granulations. 16.4 % patients required insertion of a ventriculoperitoneal shunt. The number of arachnoid granulations were a significant negative predictor of ventriculoperitoneal shunt insertion [OR: 0.251 (95% CI:0.073-0.862; P=0.028)]. There was significant difference in the number of arachnoid granulations between those with and without ventriculoperitoneal shunt (p=0.002). No patient with greater than 4 arachnoid granulations required a ventriculoperitoneal shunt, irrespective of severity of initial grade.

ConclusionArachnoid granulations may be protective against the development of shunt dependent chronic hydrocephalus after aneurysmal subarachnoid hemorrhage. This is irrespective of presenting hemorrhage severity. This is a potentially novel radiologic biomarker and anatomic predictor of shunt dependence.


sentences:
Vascular burden and cognition: Mediating roles of neurodegeneration and amyloid-PET INTRODUCTIONIt remains unclear to which extent vascular burden promotes neurodegeneration and cognitive dysfunction in a cohort spanning low-to-severe small vessel disease (SVD) and amyloid-beta pathology.

METHODSIn 120 subjects, we investigated 1) whether vascular burden, quantified as total or lobar white matter hyperintensity (WMH) volumes, is associated with different cognitive domains; and 2) whether the total WMH effect on cognition is mediated by amyloid (18F-AV45-PET), glucose metabolism (18F-FDG-PET), and/or cortical atrophy.

RESULTSIncreased total WMH volume was associated with poorer performance in all cognitive domains tested, with the strongest effects observed for semantic fluency. These relationships were mediated mainly through cortical atrophy, particularly in the temporal lobe, and to a lesser extent through amyloid and metabolism. WMH volumes differentially impacted cognition depending on lobar location and amyloid status.

DISCUSSIONOur study suggests mainly an amyloid-independent pathway in which vascular burden affects cognitive impairment through temporal lobe atrophy.


sentences:
PDGRFA-mutant gastrointestinal stromal tumours (GISTs) in Eastern England: clinicopathological features and outcomes of 50 patients diagnosed between 2008-2021 BackgroundPDGRFA-mutant gastrointestinal tumours (GISTs) comprise approximately 10% of GISTs and are mostly gastric. Targeted therapies against these tumours have historically been limited by tyrosine kinase inhibitor (TKI)-resistance. We reviewed the characteristics and outcome of all PDGRFA-mutant patients seen at our centre over the last 13 years.

MethodsAll PDGRFA-mutant patients seen at the Cambridge University Hospitals NHS Foundation Trust GIST clinic from July 2008-July 2021 were retrospectively reviewed and followed up.

Results50 PDGRFA-mutant GIST patients were diagnosed during the 13-year period. 60% were male. Median tumour size was 5 cm and the majority were epithelioid (44%) or mixed (36%) type. Commonest primary location was the gastric body (52%). In non-metastatic patients the low-risk modified AFIP risk group was the most common (65.2%). PDGFRA exon 18 (86%) were the most common PDGFRA mutations, most being imatinib resistant. None harboured a KIT mutation. 38% of cases had high KIT expression (immunohistochemistry), whilst 48% had patchy expression and 14% were negative. Most were positive for DOG1 (94%). CD34 was highly expressed in 48% of cases. 13% developed metastases during the 13-year follow-up period: liver (80%) being the commonest site. 76% of all patients underwent radical resection. 14% received TKI therapy. After a median follow-up of 55.1 months, 82% remained alive: 6 patients died from metastatic GIST; 3 from other causes. Median time to metastatic disease was 30.1 months, and median time from metastatic diagnosis to death was 18.5 months. Patients who presented with metastatic disease had the poorest survival outcome (p=0.001)

ConclusionTo date this is the largest single-centre European PDGRFA-mutant GIST cohort. Results highlight the generally indolent nature of PDGRFA-mutant disease (contrasted to the poor outcome of those who present with metastatic disease), male and gastric preponderance (unlike KIT-mutant GISTs), and variable KIT expression.

HighlightsO_LILargest single-centre European PDGFRA-mutant GIST series (n=50) to date
C_LIO_LIResults confirm the relative indolent nature of non-metastatic PDGFRA-mutant GISTs
C_LIO_LIPDGFRA-mutant GISTs had variable levels of KIT protein expression (immunohistochemistry) despite being KIT-wild type.
C_LIO_LIIn contrast to KIT-mutant GISTs, PDGFRA-mutant GISTs were more common in males and less frequent in parts of the stomach where KIT-mutant GISTS occur.
C_LIO_LIA minority of patients received TKI therapy. One patient with metastatic imatinib-resistant PDGFRA-mutant GIST had a 6 year response to imatinib.
C_LI

labels: oncology


sentences:
Persisting Chemosensory Impairments in 366 Healthcare Workers Following COVID-19: An 11-Month Follow-up. Background and ObjectivesOlfactory and gustatory dysfunctions (OD, GD) are prevalent symptoms following COVID-19 and persist in 6%-44% of individuals in the first months after the infection. As only few reports have described their prognosis more than 6 months later, the main objective of this study was to assess the prevalence of OD and GD 11 months after COVID-19. We also aimed to determine test-retest reliability of subjective chemosensory ratings for the follow-up of chemosensory sensitivity, as this measure is often used for remote follow-up.

MethodsInclusion criteria included a PCR-confirmed SARS-CoV-2 infection; exclusion criteria were the presence of other respiratory infections and chronic sinusitis. To assess whether OD and GD had changed compared to pre-pandemic levels, we designed an observational study and distributed an online questionnaire assessing quantitative chemosensory function to healthcare workers 5 and 11 months after COVID-19. Specifically, we assessed olfaction, gustation, and trigeminal sensitivity (10-point visual analog scale) and function (4-point Likert scale) separately. We further assessed clinically relevant OD using the Chemosensory Perception Test, a psychophysical test designed to provide a reliable remote olfactory evaluation. Qualitative chemosensory dysfunction was also assessed.

ResultsWe included a total of 366 participants (mean age of 44.8 years old (SD: 11.7)). They completed the last online questionnaire 10.6 months (SD: 0.7) after the onset of COVID-19 symptoms. Of all participants, 307 (83.9%) and 301 (82.2%) individuals retrospectively reported lower olfactory or gustatory sensitivity during the acute phase of COVID-19. Eleven months later, 184 (50.3%) and 163 (44.5%) indicated reduced chemosensory sensitivity, 32.2% reported impairment of olfactory function while 24.9% exhibited clinically relevant OD. Three variables predicted OD at follow-up, namely chest pain and GD during COVID-19 and presence of phantosmia at 5 months. Olfactory sensitivity ratings had a high test-retest reliability (intraclass correlation coefficient: 0.818 (95% CI: 0.760 - 0.860))

DiscussionThis study suggests that chemosensory dysfunctions persist in a third of COVID-19 patients 11 months after COVID-19. Subjective measures have a high test-retest reliability and thus can be used to monitor post-COVID-19 OD. OD appears to be a common long-term symptom of COVID-19 important to consider when treating patients.

labels: otolaryngology


sentences:
ESBL plasmids in Klebsiella pneumoniae: diversity, transmission, and contribution to infection burden in the hospital setting BackgroundResistance to third-generation cephalosporins, often mediated by extended-spectrum beta-lactamases (ESBLs), is a considerable issue in hospital-associated infections as few drugs remain for treatment. ESBL genes are often located on large plasmids that transfer horizontally between strains and species of Enterobacteriaceae and frequently confer resistance to additional drug classes. While plasmid transmission is recognised to occur in the hospital setting, the frequency and impact of plasmid transmission on infection burden, compared to ESBL+ strain transmission, is not well understood.

MethodsWe sequenced the genomes of clinical and carriage isolates of Klebsiella pneumoniae species complex from a year-long hospital surveillance study to investigate ESBL burden and plasmid transmission in an Australian hospital. Long-term persistence of a key transmitted ESBL+ plasmid was investigated via sequencing of ceftriaxone-resistant isolates during four years of follow-up, beginning three years after the initial study.

ResultsWe found 25 distinct ESBL plasmids. One (Plasmid A, carrying blaCTX-M-15 in an IncF backbone similar to pKPN-307) was transmitted at least four times into different Klebsiella species/lineages and was responsible for half of all ESBL episodes during the initial one-year study period. Three of the Plasmid A-positive strains persisted locally 3-6 years later, and Plasmid A was detected in two additional strain backgrounds. Overall Plasmid A accounted for 21% of ESBL+ infections in the follow-up period.

ConclusionsWhilst ESBL plasmid transmission events were rare in this setting, they had a significant and sustained impact on the burden of ceftriaxone-resistant and multidrug-resistant infections.

summaryWe detected a blaCTX-M-15 plasmid (Plasmid A) that transferred four times into different Klebsiella lineages, causing 50% of ESBL episodes during the initial study. Three Plasmid A-positive strains persisted locally 3-6 years later, accounting for 21% of ESBL+ infections.


sentences: Post COVID-19 1st Dose Vaccination Common Symptoms among SE Asia College Students In the second year of the COVID-19 epidemic in the Southeast Asia (SE) regions, there is a plan to reopen the school, including the campus. Among students in Indonesia, college students have a population of almost 8.3 million. Considering the massive numbers of college students, school reopening should be supported by adequate COVID-19 vaccination. As a result, the first dose of the inactivated virus COVID-19 vaccine has been administered, including to college students aged over 18 years old. While COVID-19 vaccination is widely available, there is still a scarcity of information on post-vaccination symptoms. As reported from other locations, post vaccination has been reported. Then, this study aims to assess the common symptoms of COVID-19 1st dose vaccinations among the following groups: gender (male and female college students), age, body weight, and height. The observed symptoms include sore arms, fatigue, headache, fever with a body temperature above 38 {degrees}C, nausea, shivering, and muscle joint pain. Participants in this study were students at the university. They were considered eligible for this study if they were currently enrolled at university, were at least 19 years of age, and provided informed consent. The data was recorded using a standardized online questionnaire. The answers were collected in an online database. At the beginning of the questionnaire, subjects or students were informed that data would be collected anonymously. Based on the results, the symptoms were different between female and male students. In fact, female students have experienced more symptoms than male students. While male students only suffered sore arms (68%) followed by headache symptoms (32%). Similar to male students, sore arms are the most common symptom observed among female students. Among female students, from the most to the least common symptoms observed from 20 years of age in this study are sore arms at site reaction > headache > fatigue > fever > muscle joint pain > shivering > nausea. A higher risk of presenting fatigue and headache symptoms was found in those with a non-overweight status with weight ranges of 50-60 kg.


sentences:
The shape of cancer relapse: Topological data analysis predicts recurrence in paediatric acute lymphoblastic leukaemia Acute Lymphoblastic Leukaemia (ALL) is the most frequent paediatric cancer. Modern therapies have improved survival rates, but approximately 15-20 % of patients relapse. At present, patients risk of relapse are assessed by projecting high-dimensional flow cytometry data onto a subset of biomarkers and manually estimating the shape of this reduced data. Here, we apply methods from topological data analysis (TDA), which quantify shape in data via features such as connected components and loops, to pre-treatment ALL datasets with known outcomes. We combine these fully unsupervised analyses with machine learning to identify features in the pre-treatment data that are prognostic for risk of relapse. We find significant topological differences between relapsing and non-relapsing patients and confirm the predictive power of CD10, CD20, CD38, and CD45. Further, we are able to use the TDA descriptors to predict patients who relapsed. We propose three prognostic pipelines that readily extend to other haematological malignancies.

TeaserTopology reveals features in flow cytometry data which predict relapse of patients with acute lymphoblastic leukemia

labels: hematology


sentences: Cooccurrence of N501Y, P681R and other key mutations in SARS-CoV-2 Spike Analysis of circa 4.2 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome sequences on  Global Initiative on Sharing All Influenza Data (GISAID) shows the spike mutations  N501Y (common to Alpha, Beta, Gamma, Omicron variants) and  P681R (central to Delta variants spread) have cooccurred 3,678 times between 17 October 2020 and 1 November 2021. In contrast, the N501Y+P681H combination is present in Alpha and Omicron variants and circa 1.1 million entries. Two-thirds of the 3,678 cooccurrences were in France, Turkey or US (East Coast), and the rest across 62 other countries. 55.5% and 4.6% of the cooccurrences were Alphas Q.4 and Gammas P.1.8 sub-lineages acquiring P681R; 10.7% and 3.8% were Deltas B.1.617.2 lineage and AY.33 sub-lineage acquiring N501Y; remaining 10.2% were in other variants. Despite the selective advantages individually conferred by N501Y and P681R, the N501Y+P681R combination counterintuitively didnt outcompete other variants in every instance. Although a relief to worldwide public health efforts, in vitro and in vivo studies are urgently required in the absence of a strong in silico explanation for this phenomenon. This study demonstrates a pipeline to analyse combinations of key mutations from public domain information in a systematic manner and provide early warnings of spread.


sentences: Interpretable and Predictive Deep Modeling of the SARS-CoV-2 Spike Protein Sequence As the COVID-19 pandemic continues, the SARS-CoV-2 virus continues to rapidly mutate and change in ways that impact virulence, transmissibility, and immune evasion. Genome sequencing is a critical tool, as other biological techniques can be more costly, time-consuming, and difficult. However, the rapid and complex evolution of SARS-CoV-2 challenges conventional sequence analysis methods like phylogenetic analysis. The virus picks up and loses mutations independently in multiple subclades, often in novel or unexpected combinations, and, as for the newly emerged Omicron variant, sometimes with long explained branches. We propose interpretable deep sequence models trained by machine learning to complement conventional methods. We apply Transformer-based neural network models developed for natural language processing to analyze protein sequences. We add network layers to generate sample embeddings and sequence-wide attention to interpret models and visualize multiscale patterns. We demonstrate and validate our framework by modeling SARS-CoV-2 and coronavirus taxonomy. We then develop an interpretable predictive model of disease severity that integrates SARS-CoV-2 spike protein sequence and patient demographic variables, using publicly available data from the GISAID database. We also apply our model to Omicron. Based on knowledge prior to the availability of empirical data for Omicron, we predict: 1) reduced neutralization antibody activity (15-50 fold) greater than any previously characterized variant, varying between Omicron sublineages, and 2) reduced risk of severe disease (by 35-40%) relative to Delta. Both predictions are in accord with recent epidemiological and experimental data.


sentences:
Home Monitoring for Fever: An Inexpensive Screening Method to Prevent Household Spread of COVID-19 The COVID-19 pandemic surge has exceeded testing capacities in many parts of the world. We investigated the effectiveness of home temperature monitoring for early identification of COVID-19 patients.

Study DesignWe compared home temperature measurements from a convenience sample of 1180 individuals who reported being test positive for SARS-CoV-2 to an age, sex, and location matched control group of 1249 individuals who had not tested positive.

MethodsAll individuals monitored their temperature at home using an electronic smartphone thermometer that relayed temperature measurements and symptoms to a centralized cloud based, de-identified data bank.

ResultsIndividuals varied in the number of times they monitored their temperature. When temperature was monitored for over 72 hours fever (> 37.6{degrees}C or 99.7{degrees}F or a change in temperature of > 1{degrees}C or 1.8{degrees}F) was detected in 73% of test positive individuals, a sensitivity comparable to rapid SARS-CoV-2 antigen tests. When compared our control group the specificity of fever for COVID-19 was 0.70. However, when fever was combined with complaints of loss of taste and smell, difficulty breathing, fatigue, chills, diarrhea, or stuffy nose the odds ratio of having COVID-19 was sufficiently high as to obviate the need to employ RTPCR or antigen testing to screen for and isolate coronavirus infected cases.

ConclusionsOur findings suggest that home temperature monitoring could serve as an inexpensive convenient screen for the onset of COVID-19, encourage earlier isolation of potentially infected individuals, and more effectively reduce the spread of infection in closed spaces.


sentences:
Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods PurposeHow completely do hospital discharge diagnoses identify cases of myopericarditis after an mRNA vaccine?

MethodsWe assembled a cohort 12 to 39 years old patients, insured by Kaiser Permanente Northwest, who received at least one dose of an mRNA vaccine (Pfizer-BioNTech or Moderna) between December 2020 and October 2021. We followed them for up to 30 days after their second dose of an mRNA vaccine to identify encounters for myocarditis, pericarditis or myopericarditis. We compared two identification methods: A method that searched all encounter diagnoses using a brief text description (e.g., ICD-10-CM code I40.9 is defined as  acute myocarditis, unspecified). We searched the text description of all inpatient or outpatient encounter diagnoses (in any position) for "myocarditis" or "pericarditis." The other method was developed by the Centers for Disease Control and Preventions Vaccine Safety Datalink (VSD), which searched for emergency department visits or hospitalizations with a select set of discharge ICD-10-CM diagnosis codes. For both methods, two physicians independently reviewed the identified patient records and classified them as confirmed, probable or not cases using the CDCs case definition.

ResultsThe encounter methodology identified 14 distinct patients who met the confirmed or probable CDC case definition for acute myocarditis or pericarditis with an onset within 21 days of receipt of COVID-19 vaccination. Three of these 14 patients had an ICD-10 code of I51.4 "Myocarditis, Unspecified" which was overlooked by the VSD algorithm. The VSD methodology identified 11 patients who met the CDC case definition for acute myocarditis or pericarditis. Seven (64%) of the eleven patients had initial care for myopericarditis outside of a KPNW facility and their diagnosis could not be ascertained by the VSD methodology until claims were submitted (median delay of 33 days; range of 12-195 days). Among those who received a second dose of vaccine (n=146,785), we estimated a risk as 95.4 cases of myopericarditis per million second doses administered (95% CI, 52.1 to 160.0).

ConclusionWe identified additional valid cases of myopericarditis following an mRNA vaccination that would be missed by the VSDs search algorithm, which depends on select hospital discharge diagnosis codes. The true incidence of myopericarditis is markedly higher than the incidence reported to US advisory committees. The VSD should validate its search algorithm to improve its sensitivity for myopericarditis.

Key PointsO_LIWe identified a higher estimate of myopericarditis following COVID-19 mRNA vaccine by searching encounter text description compared with the Vaccine Safety Datalink (VSD) methodology
C_LIO_LIAn incomplete list of ICD-10 codes and delays in hospital claims data were responsible for the difference
C_LIO_LIWe estimated a risk of 95.4 cases of myopericarditis per million second doses administered in patients age 12-39 which is higher than the incidence reported to US advisory committees
C_LIO_LIWe encourage other VSD sites to validate the case ascertainment of current VSD methodology
C_LI


sentences:
Transmission of SARS-CoV-2 among children and staff in German daycare centers: results from the COALA study BackgroundWhereas the majority of children under 6 years of age attend daycare centers in Germany, evidence on the role of daycare centers in the transmission of SARS-CoV-2 is scarce.

AimsThis study aims to investigate the transmission risk in daycare centers among children and staff and the spread of infections to associated households.

Methods30 daycare groups with at least one recent laboratory-confirmed SARS-CoV-2 case (child or staff) were enrolled in the study (10/2020-06/2021). Close contacts within the daycare group and households were examined over a 12-day period (repeated SARS-CoV-2 PCR tests, genetic sequencing of viruses, documentation of symptoms). Households, local health authorities and daycare staff were interviewed to gain comprehensive information on each outbreak. We determined primary cases for all daycare groups.

ResultsThe number of secondary cases varied considerably between daycare groups. The pooled secondary attack rate (SAR) across all 30 daycare centers was 9.6%. The SAR tended to be higher in daycare centers in which the Alpha variant of the virus was detected (15.9% vs. 5.1% with evidence of wild type). The SAR in households was 53.3%. Exposed children were less likely to get infected with SARS-CoV-2 in daycare centers, compared to adults (7.7% vs. 15.5%).

ConclusionContainment measures in daycare programs are critical and become increasingly important with highly transmissible new variants to reduce SARS-CoV-2 transmission, especially to avoid spread to associated households. Virus variants may modify transmission dynamics in daycare programs.


sentences: Controlling the worldwide chaotic spreading of COVID-19 through vaccinations The striking differences and similarities between the  Spanish-flu of 1918 and the Coronavirus disease of 2019 (COVID-19) are analyzed. Progress in medicine and technology and in particular the availability of vaccines has decreased the death probability from about 2% for the Spanish-flu, to about 10-4 in the UK and 10-3 in Italy, USA, Canada, San Marino and other countries for COVID-19. The logistic map reproduces most features of the disease and may be of guidance for predictions and future steps to be taken in order to contrast the virus. We estimate 6.4 x 107 deceases worldwide without the vaccines, this value decreases to 2.4 x 107 with the current vaccination rate. In November 2021, the number of deceased worldwide was 5.1 x 106. To reduce the fatalities further, it is imperative to increase the vaccination rate worldwide to at least 120 millions/day and the AstraZeneca vaccine due to its efficacity and cost is a possible route to accomplish this.


sentences: Antibody therapy reverses biological signatures of COVID-19 progression Understanding who is at risk of progression to severe COVID-19 is key to effective treatment. We studied correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the treatment of SARS-CoV-2 infection. Several laboratory parameters identified study participants at greater risk of severe disease, including a high neutrophil-lymphocyte ratio (NLR), a negative SARS-CoV-2 serologic test and whole blood transcriptome profiles. Sotrovimab treatment in these groups was associated with normalization of NLR and the transcriptomic profile, and with a decrease of viral RNA in nasopharyngeal samples. Transcriptomics provided the most sensitive detection of participants who would go on to be hospitalized or die. To facilitate timely measurement, we identified a 10-gene signature with similar predictive accuracy. In summary, we identified markers of risk for disease progression and demonstrated that normalization of these parameters occurs with antibody treatment of established infection.


sentences: Reliably Assessing Duration of Protection for COVID-19 Vaccines Decision-making about booster dosing for COVID-19 vaccine recipients hinges on reliable methods for evaluating the longevity of vaccine protection. We show that modeling of protection as a piecewise linear function of time since vaccination for the log hazard ratio of the vaccine effect provides more reliable estimates of vaccine effectiveness at the end of an observation period and also more reliably detects plateaus in protective effectiveness as compared with the traditional method of estimating a constant vaccine effect over each time period. This approach will be useful for analyzing data pertaining to COVID-19 vaccines and other vaccines where rapid and reliable understanding of vaccine effectiveness over time is desired.


sentences: Immunosequencing and epitope mapping reveal substantial preservation of the T cell immune response to Omicron generated by SARS-CoV-2 vaccines The Omicron SARS-CoV-2 variant contains 34 mutations in the spike gene likely impacting protective efficacy from vaccines. We evaluated the potential impact of these mutations on the cellular immune response. Combining epitope mapping to SARS-CoV-2 vaccines that we have determined from past experiments along with T cell receptor (TCR) repertoire sequencing from thousands of vaccinated or naturally infected individuals, we estimate the abrogation of the cellular immune response in Omicron. Although 20% of CD4+ T cell epitopes are potentially affected, the loss of immunity mediated by CD4+ T cells is estimated to be slightly above 30% as some of the affected epitopes are relatively more immunogenic. For CD8+ T cells, we estimate a loss of approximately 20%. These reductions in T cell immunity are substantially larger than observed in other widely distributed variants. Combined with the expected substantial loss of neutralization from antibodies, the overall protection provided by SARS-CoV-2 vaccines could be impacted adversely. From analysis of prior variants, the efficacy of vaccines against symptomatic infection has been largely maintained and is strongly correlated with the T cell response but not as strongly with the neutralizing antibody response. We expect the remaining 70% to 80% of on-target T cells induced by SARS-CoV-2 vaccination to reduce morbidity and mortality from infection with Omicron.


sentences:
High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron The early widespread dissemination of Omicron indicates the urgent need to better understand the transmission dynamics of this variant, including asymptomatic spread among immunocompetent and immunosuppressed populations. In early December 2021, the Ubuntu clinical trial, designed to evaluate efficacy of the mRNA-1273 vaccine (Moderna) among persons living with HIV (PLWH), began enrolling participants. Nasal swabs are routinely obtained at the initial vaccination visit, which requires participants to be clinically well to receive their initial jab. Of the initial 230 participants enrolled between December 2 and December 17, 2021, 71 (31%) were PCR positive for SARS-CoV-2: all of whom were subsequently confirmed by S gene dropout to be Omicron; 48% of the tested samples had cycle threshold (CT) values <25 and 18% less than 20, indicative of high titers of asymptomatic shedding. Asymptomatic carriage rates were similar in SARS-CoV-2 seropositive and seronegative persons (27% respectively). These data are in stark contrast to COVID-19 vaccine studies conducted pre-Omicron, where the SARS-CoV-2 PCR positivity rate at the first vaccination visit ranged from <1%-2.4%, including a cohort of over 1,200 PLWH largely enrolled in South Africa during the Beta outbreak. We also evaluated asymptomatic carriage in a sub study of the Sisonke vaccine trial conducted in South African health care workers, which indicated 2.6% asymptomatic carriage during the Beta and Delta outbreaks and subsequently rose to 16% in both PLWH and PHLWH during the Omicron period.

These findings strongly suggest that Omicron has a much higher rate of asymptomatic carriage than other VOC and this high prevalence of asymptomatic infection is likely a major factor in the widespread, rapid dissemination of the variant globally, even among populations with high prior rates of SARS-COV-2 infection.


sentences:
The Canadian COVID-19 Experiences Survey: Study Protocol IntroductionVaccine hesitancy and inconsistent mitigation behavior performance have been significant challenges throughout the COVID-19 pandemic. In Canada, despite relatively high vaccine availability and uptake, willingness to accept booster shots and maintain mitigation behaviors in the post-acute phase of COVID-19 remain uncertain. The aim of the Canadian COVID-19 Experiences Project (CCEP) is two-fold: 1) to identify social-cognitive and neurocognitive correlates of vaccine hesitancy and mitigation behaviors, and 2) to identify optimal communication strategies to promote vaccination and mitigation behaviors into the post-acute phase of the pandemic.

Methods and analysesThe CCEP is comprised of two components: a conventional population survey (Study 1) and a functionally interconnected laboratory study (Study 2). Study 1 will involve 3 waves of data collection. Wave 1, completed between 28 September and 21 October, 2021, recruited 1,958 vaccine-hesitant (49.8%) and fully vaccinated (50.2%) adults using quota sampling to ensure maximum statistical power. Measures included a variety of social cognitive (e.g., beliefs, intentions) and neurocognitive (e.g., delay discounting) measures, followed by an opportunity to view and rate a set of professionally produced COVID-19 public service announcement (PSA) videos for perceived efficacy. Study 2 employs the same survey items and PSAs but coupled with lab-based eye tracking and functional brain imaging to directly quantify neural indicators of attention capture and self-reflection in a smaller community sample. In the final phase of the project, subjective impressions and neural indicators of PSA efficacy will be compared and used to inform recommendations for construction of COVID-19 PSAs into the post-acute phase of the pandemic.

Ethics and disseminationThe CCEP has received ethical review and approval by the University of Waterloo Office of Research Ethics. Findings will be disseminated through peer-reviewed publications and presentations at scientific meetings.


sentences: BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19 Reports suggest that COVID-19 vaccine effectiveness is decreasing, either due to waning immune protection, emergence of new variants of concern, or both. Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) appeared to be superior in inducing protective immunity, and large scale second booster vaccination is ongoing. However, data comparing declining immunity after homologous and heterologous vaccination as well as effects of a third vaccine application after heterologous ChAd/BNT vaccination are lacking. We longitudinally monitored immunity in ChAd/ChAd (n=41) and ChAd/BNT (n=88) vaccinated individuals and assessed the impact of a second booster with BNT in both groups. The second booster greatly augmented waning anti-spike IgG but only moderately increased spike-specific CD4+ and CD8+ T cells in both groups to cell frequencies already present after the boost. More importantly, the second booster efficiently restored neutralizing antibody responses against Alpha, Beta, Gamma, and Delta, but neutralizing activity against B.1.1.529 (Omicron) stayed severely impaired. Our data suggest that inferior SARS-CoV-2 specific immune responses after homologous ChAd/ChAd vaccination can be cured by a heterologous BNT vaccination. However, prior heterologous ChAd/BNT vaccination provides no additional benefit for spike-specific T cell immunity or neutralizing Omicron after the second boost.


sentences:
Durability of Response to a Third BNT162b2 Vaccine in Adults >=60 Years BackgroundAge/frailty are strong predictors of COVID-19 mortality. After the second BNT162b2 dose, immunity wanes faster in older ([≥]65 years) versus younger adults. The durability of response after the third vaccine is unclear.

MethodsThis prospective cohort study included healthcare workers/family members[≥]60 years who received a third BNT162b2 dose. Blood samples were drawn immediately before (T0), 10{square}19 (T1), and 74{square}103 (T2) days after the third dose. Anti-spike IgG titers were determined using a commercial assay, seropositivity was defined as[≥]50 AU/mL. Neutralising antibody titres were determined at T2. Adverse events, COVID-19 infections, and clinical frailty scale (CFS) levels were documented.

FindingsThe analysis included 97 participants (median age, 70 years [IQR, 66{square}74], 58% CFS level 2). IgG titres, which increased significantly from T0 to T1 (medians, 440 AU/mL [IQR, 294{square}923] and 25,429 [14203{square}36114] AU/mL, respectively; p<0{middle dot}001), decreased significantly by T2, but all remained seropositive (median, 8306 AU/mL [IQR, 4595{square}14701], p<0{middle dot}001 vs T1). In a multivariable analysis, only time from the first vaccine was significantly associated with lower IgG levels at T2 (p=0{middle dot}004). At T2, 60 patients were evaluated for neutralising antibodies; all were seropositive (median, 1294 antibody titre [IQR, 848{square}2072]). Neutralising antibody and anti-spike IgG levels were correlated (R=0{middle dot}6, p<0{middle dot}001). No major adverse events or COVID-19 infections were reported.

InterpretationAnti-spike IgG and neutralising antibody levels remain adequate 3 months after the third BNT162b2 vaccine in healthy adults[≥]60 years, although the decline in IgG is concerning. A third vaccine dose in this population should be top priority.

FundingNo external funding.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed on Aug 1, 2021, for published research articles with no date restrictions, using the search terms of "SARS-Cov-2", "COVID-19", "vaccine", "dose", "antibody response", and "adults" with English as a filter. Several studies were identified that investigated waning of immunity in healthy adults. It is well established through epidemiology and serology studies that in healthy adults, the protection conferred by the BNT162b2 messenger RNA (mRNA) vaccine (Pfizer/BioNtech) wanes significantly after several months. Studies have also shown that the immune response to the vaccine varies with age, and that after the second dose of the BNT162b2 vaccine, the older adult population (65-85 years of age) typically has a lower immune response (as reflected in an analysis of anti-spike IgG antibodies and neutralising antibody titres), than younger adults (18-55 years of age), and that the immunity wanes in all age groups within several months.

Added value of this studyThis is, to our knowledge, the first study that examined anti-spike IgG and neutralising antibody titres three months after the third BNT162b2 vaccine dose. The study has demonstrated that three months after that dose, participants, who were healthy adults aged 60 years and older, remained anti-spike IgG seropositive, although a significant decrease in anti-spike IgG titres was observed (compared to two weeks after the third dose). In addition, a statistically significant correlation was observed between the neutralising antibody titres and the anti-spike IgG titres, and all participants were seropositive for neutralising antibodies three months after the third dose. Also, no major adverse events or COVID-19 infections were reported.

Implications of all the available evidenceAs our data suggest that a third dose of the BNT162b2 vaccine is effective in maintaining adequate immune response against COVID-19 for at least several months in healthy adults aged 60 years and older, and as it is well established that older adults are at higher risk of severe COVID-19 disease and COVID-19 mortality, providing a third dose to this population should be a top priority. Our data also highlight that understanding the waning of the immune response in other age groups is key for making evidence-based policies regarding booster vaccinations for the population at large.


sentences: Detection of the omicron variant virus with the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay The US Centers for Disease Control and Prevention recommends rapid testing for SARS-CoV-2 infection as a key element of epidemic control. The Abbott BinaxNow is in widespread use in the United States for self-testing and as part of public health screening campaigns, but has not been evaluated for use with the omicron variant of SARS-CoV-2. We recruited individuals testing positive for COVID-19 PCR at an academic medical center. Anterior nasal swabs were stored in viral transport media and evaluated by viral load quantification and whole genome sequencing. We created serial dilutions from 2.5x103-2.5x105 viral copies/specimen for two delta and omicron specimens, respectively, and tested each with the BinaxNow assay per manufacturer instructions. Results were interpreted by three readers, blinded to the specimen variant and concentration. All omicron and delta specimens with concentrations of 100,000 copies/swab or greater were positive by the BinaxNow Assay, a concentration similar to previously reported limits of detection for this assay. Assay sensitivity diminished below that. This study demonstrates that Omicron variant SARS-CoV-2 infections are detected by the BinaxNow rapid antigen assay. Additional laboratory and clinical validation assessments are needed to better determine their limits of detection and performance in real-world settings.